普通干扰素1b联合利巴韦林治疗非1b型慢性丙型肝炎患者临床观察

Combination of interferon alfa-1b and ribavirin in the treatment of patients with chronic hepatitis C of non-1b

目的探讨不同基因型HCV感染者对普通干扰素联合利巴韦林治疗的疗效。方法应用型特异性探针杂交法检测106例慢性丙型肝炎患者HCV基因型。应用普通干扰素联合利巴韦林治疗,观察病毒学应答情况。结果在106例患者中,以HCV 3b(45.3%)、1b(20.8%)和3a(18.9%)型为主,6a(9.4%)和2a(5.7%)型次之;在22例1b型感染者,只有9例接受本治疗方案,82例非1b型感染者完成治疗。非1b型患者的RVR和EVR分别为50%和86.6%;在1b型HCV感染者,22.2%(2/9)获得SVR,而非1b型HCV感染者,76.8%(63/82)获得SVR。结论普通干扰素联合利巴韦林治疗非1b型慢性丙型肝炎患者疗效较好。

Objective To investigate the efficacies of interferon alfa-1b and ribavirin in treatment of patients with chronic hepatitis C of different genotypes.Methods The genotypes of hepatitis C virus in 106 patients with hepatitis C were detected by genotype-specific probes.The patients with hepatitis C were treated with interferon alfa-1b and ribavirin for 48 weeks.Results Out of 106 patients with hepatitis C,the HCV genotype 3b accounted for 45.3%,1b for 20.8%,and 3a for 18.9%,while we still detected some 6a（9.4%）and 2a（5.7%） positive;Nine out of 22 patients with hepatitis C of 1b and other 82 with non-1b finished the regimen;the rapid virological response and early virological response in patient with non-1b were 50% and 86.6%,respectively;22.2%（2/9）of 1b infected patients got sustained virological response,while 76.8%（63/82）of non-1b got SVR.Conclusion Interferon alfa-1b and ribavirin regimen can be selected for hepatitis C patients with non-1b infection.